This combination therapy of inhibiting both the proteasome and HDAC6 also seemed to work well in ovarian cancer cells with the treatment of bortezomib and the HDAC6-specific inhibitor NK84. This evidence concerns the gene HDAC6 and ovarian carcinoma.